CT Atlantic AG Announces Appointment of Thomas Lander to the Board of Directors

16-Sep-2010 - Switzerland

CT Atlantic AG announced the appointment of Dr. Thomas Lander to its board of directors. Thomas Lander provides CT Atlantic with long-standing, global pharmaceutical experience in early through late stage drug development and in regulatory affairs.

Dr. Lander was previously Managing Director of CureVac GmbH (Tübingen, Germany) where he led the development of two mRNA-derived tumor vaccines for the treatment of prostate and non-small cell lung cancer. He is currently an advisor to biotechnology companies and related investment funds. Between 2003 and 2006, Dr. Lander was Executive Vice President, Global Clinical Research and Development and Chief Medical Officer with Merck KGaA (Darmstadt, Germany) where he led the global clinical development of Merck’s oncology pipeline including the successful approval and launch of the EGF receptor inhibiting antibody Erbitux® against colorectal, head and neck cancer.

Dr. Lander holds an MD degree from the Ludwig-Maximilians-Universität, Medical School, Munich, and is a Certified Diabetologist. Prior to his appointment at Merck, Dr. Lander held several senior management positions in clinical development with international pharmaceutical companies including GlaxoSmithKline, Bristol-Myers Squibb, NovoNordisk and Boehringer Ingelheim. He serves on the board of Lipid Therapeutics GmbH, Heidelberg, and Vasopharm GmbH, Würzburg, as a director.

https://www.bionity.com/en/news/122923/ct-atlantic-ag-announces-appointment-of-thomas-lander-to-the-board-of-directors.html